Sanofi Working To Resolve GMP Issues That Derailed Sarilumab Approval

CEO Olivier Brandicourt says Sanofi's Le Train, France, fill-and-finish facility should be back in FDA’s good graces before the PDUFA goal date for another Sanofi antibody, dupilumab.